Surging Prevalence Of Lung Cancer Drives Expansion In The Lung Cancer Diagnostic And Screening Market: Key Factor Driving The Growth In The Lung Cancer Diagnostic And Screening Market

The Lung Cancer Diagnostic And Screening Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Expected Lung Cancer Diagnostic And Screening Market Size During the Forecast Period?
The dimension of the lung cancer diagnostic and screening market has expanded significantly in the past few years. There will be a surge from $2.34 billion in 2024 to $2.56 billion in 2025, representing a compound annual growth rate (CAGR) of 9.6%. The historical period growth is associated with advancements in digital imaging, standardization of screening procedures, public health campaigns to reduce tobacco consumption, cancer registries establishment, and progress in pathology analysis.

In the coming years, the market size of lung cancer diagnostic and screening is predicted to witness significant growth, reaching a value of $3.69 billion in 2029 with a compound annual growth rate (CAGR) of 9.5%. The anticipated growth during this forecast period is due to the surge in lung cancer incidence, an increased focus on early diagnosis, the development of extensive high-risk screening programs, a shift towards personalized treatment approaches, and government-backed initiatives and funding. The forecast period is expected to see the development of new screening methods, advances in biomarker testing, the incorporation of artificial intelligence (AI), a rise in the usage of liquid biopsies, a concentration on early stage detection, and the growth of low-dose CT screening programs.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12043

What Are the High-Growth Segments in the Lung Cancer Diagnostic And Screening Market?
The lung cancer diagnostic and screening market covered in this report is segmented -

1) By Product: Instruments, Consumables And Accessories
2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests
3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer
4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users

Subsegments:
1) By Instruments: Imaging Devices, Biopsy Devices, Bronchoscopy Systems
2) By Consumables And Accessories: Biopsy Needles, Reagents And Assays, Imaging Contrast Agents, Patient Preparation Equipment, Sample Collection Kits, Laboratory Supplies

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp

What Key Drivers Are Expected to Influence Future Lung Cancer Diagnostic And Screening Market Growth?
The lung cancer diagnostic and screening market is forecasted to expand due to the rising incidence of lung cancer. This malignant disease, characterized by unrestricted growth of abnormal cells in the lung tissues, may cause symptoms such as coughing, chest pain, and difficulty in breathing. Early detection and diagnosis of lung cancer are made possible through various tests, like incisional biopsies and bronchoscopies. The American Cancer Society, a government organization based in the U.S., reported in January 2023 that there were an estimated 238,340 new lung cancer cases (117,550 in men and 120,790 in women) in the United States. The organization also reported 127,070 deaths due to lung cancer (67,160 in men and 59,910 in women). Thus, the escalating incidence of lung cancer is fuelling the growth of the lung cancer diagnostic and screening market.

Which Companies Hold the Largest Share Across Different Lung Cancer Diagnostic And Screening Market Segments?
Major companies operating in the lung cancer diagnostic and screening market include Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, OncimmuneHoldings Plc, Broncus Medical Inc., OncoCyte, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix,

What Trends Are Driving Growth in The Lung Cancer Diagnostic And Screening Market?
Significant players in the field of lung cancer diagnostics and screening are honing technologies like lung cancer assessments to improve early detection, refine diagnostic precision, and extend personalized treatment tactics to patients with a high risk of contracting the disease. Lung cancer assessments are diagnostic methods aimed at finding signs of lung cancer through a variety of techniques, including imaging, biomarker study, and cytology tests. For example, in December 2023, Freenome, a biotech firm based in the USA, introduced PROACT LUNG. This trial is an encouraging move towards transforming lung cancer screening, potentially resulting in earlier detection and improved patient prognoses by resolving the current shortcomings in screening procedures.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

What Are the Emerging Geographies for The Lung Cancer Diagnostic And Screening Market Growth?
North America was the largest region in the lung cancer diagnostic and screening market in 2024. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Lung Cancer Diagnostic And Screening Market?
2. What is the CAGR expected in the Lung Cancer Diagnostic And Screening Market?
3. What Are the Key Innovations Transforming the Lung Cancer Diagnostic And Screening Industry?
4. Which Region Is Leading the Lung Cancer Diagnostic And Screening Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.